JP2010540593A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540593A5
JP2010540593A5 JP2010527450A JP2010527450A JP2010540593A5 JP 2010540593 A5 JP2010540593 A5 JP 2010540593A5 JP 2010527450 A JP2010527450 A JP 2010527450A JP 2010527450 A JP2010527450 A JP 2010527450A JP 2010540593 A5 JP2010540593 A5 JP 2010540593A5
Authority
JP
Japan
Prior art keywords
disease
asthma
dermatitis
syndrome
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010527450A
Other languages
English (en)
Japanese (ja)
Other versions
JP5727223B2 (ja
JP2010540593A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/063185 external-priority patent/WO2009043890A1/en
Publication of JP2010540593A publication Critical patent/JP2010540593A/ja
Publication of JP2010540593A5 publication Critical patent/JP2010540593A5/ja
Application granted granted Critical
Publication of JP5727223B2 publication Critical patent/JP5727223B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010527450A 2007-10-04 2008-10-01 オキサジアゾール・ジアリール化合物 Expired - Fee Related JP5727223B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07117925.3 2007-10-04
EP07117925 2007-10-04
US99813607P 2007-10-09 2007-10-09
US60/998,136 2007-10-09
PCT/EP2008/063185 WO2009043890A1 (en) 2007-10-04 2008-10-01 Oxadiazole diaryl compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014197234A Division JP2015025001A (ja) 2007-10-04 2014-09-26 オキサジアゾール・ジアリール化合物

Publications (3)

Publication Number Publication Date
JP2010540593A JP2010540593A (ja) 2010-12-24
JP2010540593A5 true JP2010540593A5 (enExample) 2013-10-24
JP5727223B2 JP5727223B2 (ja) 2015-06-03

Family

ID=38961274

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010527450A Expired - Fee Related JP5727223B2 (ja) 2007-10-04 2008-10-01 オキサジアゾール・ジアリール化合物
JP2014197234A Withdrawn JP2015025001A (ja) 2007-10-04 2014-09-26 オキサジアゾール・ジアリール化合物
JP2016100693A Expired - Fee Related JP6224771B2 (ja) 2007-10-04 2016-05-19 オキサジアゾール・ジアリール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014197234A Withdrawn JP2015025001A (ja) 2007-10-04 2014-09-26 オキサジアゾール・ジアリール化合物
JP2016100693A Expired - Fee Related JP6224771B2 (ja) 2007-10-04 2016-05-19 オキサジアゾール・ジアリール化合物

Country Status (15)

Country Link
US (2) US8404676B2 (enExample)
EP (1) EP2193126B1 (enExample)
JP (3) JP5727223B2 (enExample)
KR (1) KR20100083814A (enExample)
CN (2) CN104478821B (enExample)
AR (1) AR068730A1 (enExample)
AU (1) AU2008306886B2 (enExample)
BR (1) BRPI0817597A2 (enExample)
CA (1) CA2696829C (enExample)
EA (1) EA201070423A1 (enExample)
ES (1) ES2547877T3 (enExample)
IL (1) IL204520A (enExample)
MX (1) MX2010003614A (enExample)
WO (1) WO2009043890A1 (enExample)
ZA (1) ZA201001217B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
AU2008306886B2 (en) * 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
US8551463B2 (en) 2007-10-22 2013-10-08 Living Proof, Inc. Hair care compositions and methods of treating hair
CN101918395B (zh) * 2007-12-21 2014-04-16 默克雪兰诺有限公司 三唑联噁二唑衍生物
JP5411877B2 (ja) * 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
JP5481395B2 (ja) 2008-03-07 2014-04-23 アクテリオン ファーマシューティカルズ リミテッド 新規なアミノメチルベンゼン誘導体
WO2010085584A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
SI2454255T1 (sl) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot agonisti s1p1/edg1
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
US8318783B2 (en) 2010-04-27 2012-11-27 Allergan, Inc. 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
KR101869120B1 (ko) 2011-01-19 2018-06-19 이도르시아 파마슈티컬스 리미티드 2-메톡시-피리딘-4-일 유도체
US9073881B2 (en) * 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
EP4240350A4 (en) * 2020-11-09 2024-09-18 Arena Pharmaceuticals, Inc. <sup2/>? <sub2/>?1?methods of treating conditions related to the s1preceptor
EP4050002A1 (en) * 2021-02-26 2022-08-31 First Health Pharmaceuticals B.V. Anti-proliferative agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH623971B5 (de) 1976-06-04 1982-01-15 Hoechst Ag Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller.
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
EP3345895B1 (en) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク エンド カムパニー インコーポレーテッド S1p受容体作働薬としての3−(2−アミノ−1−アザシクロ)−5−アリール−1,2,4−オキサジアゾール類
AU2004277947A1 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1-磷酸(内皮分化基因)受体激动剂的(3,4-二取代)丙酸酯
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US8022063B2 (en) 2004-05-29 2011-09-20 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
WO2006047195A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
MX2009003129A (es) 2006-09-29 2009-04-06 Novartis Ag Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US8202865B2 (en) * 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
AU2008306886B2 (en) * 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds

Similar Documents

Publication Publication Date Title
JP2010540593A5 (enExample)
JP6506836B2 (ja) B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
JP2007515432A5 (enExample)
JP7787063B2 (ja) オーロラキナーゼ阻害剤およびその使用
JP2006528980A5 (enExample)
KR102212975B1 (ko) 피리딘-4-일 유도체
JP2009534407A5 (enExample)
JP2009535307A5 (enExample)
JP2019510787A5 (enExample)
JP2019533696A (ja) B型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン
JP2015535832A5 (enExample)
JP2013514980A5 (enExample)
JP2009532417A5 (enExample)
JP2014532716A5 (enExample)
TW200806652A (en) N-hydroxyacrylamide compounds
JP2007522142A5 (enExample)
ES2548258T3 (es) Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
JP6781848B2 (ja) 新規なピロロピリジン誘導体、その製造方法及び用途
HRP20211121T1 (hr) Supstituirani biciklični spojevi
WO2023169572A1 (zh) 一种三嗪类化合物、其中间体、其制备方法及其用途
JP2007503432A5 (enExample)
JP2022526827A (ja) (e)-3-[2-(2-チエニル)ビニル]-1h-ピラゾールの固体形態
JP3539926B2 (ja) 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法
JP2018510192A5 (enExample)
US9340539B2 (en) Hepatitis C inhibitor compounds